Import and Export of Medicines: a regulated process and essential for health

The Brazilian pharmaceutical sector continues on a path of significant growth. Between 2018 and 2023, revenue jumped from R$ 90.5 billion to R$ 146.7 billion, an increase of approximately 62% as a percentage of total revenue, particularly in the institutional segment (hospitals and clinics), which grew by 74% during the period.

In addition, recent projections indicate that the market could reach US$ 21.3 billion as early as 2025, maintaining an average growth rate andbetween 5% and 6% per year through 2030.

This period of expansion, therefore, underscores the need to focus on drug logistics, especially given the growth in the volume of imports and exports of inputs—both domestically and internationally.

A Growing Market and the Importance of Logistics

According to a study by the Grand View Research, the pharmaceutical logistics market in Brazil alone generated US$ 1.578 billion in 2024. By 2033, this figure could nearly double, reaching US$ 3.45 billion—with an annual growth rate exceeding 9%. This growth is driven primarily by the cold chain, which involves temperature-sensitive medications.

Therefore, logistics has evolved from an operational support function to a strategic factor in competitiveness.

International Certifications and Standards

To engage in the export of raw materials or medicines, Brazilian companies must prepare to meet the program’s requirements Authorized Economic Operator (AEO) — a seal that certifies security and compliance in foreign trade operations.

This program, in line with World Customs Organization (SAFE Framework) reduces customs delays and increases efficiency in the international supply chain. In other words, having AEO certification is not just a competitive advantage: in many cases, it is a requirement for ensuring the smooth flow of goods.

Infrastructure and Government Initiatives

The Brazilian government has also been investing heavily in the healthcare industry. Through the Healthcare Economic-Industrial Complex, were announced R$: 42 billion in funding by 2026 with the goal of strengthening local production, reducing dependence on imports, and transforming Brazil into a regional hub for the sector.

As a result, demand for specialized logistics operations is expected to grow across the board—from production to distribution.

Why does this matter for pharmaceutical logistics?

The expansion of domestic production and the increase in exports make high-quality logistics essential. It is necessary to act with end-to-end traceability, validated storage, and integration with regulatory systems—both from the ANVISA as well as international agencies.

At the same time, the growth of the cold chain requires air-conditioned vehicles, constant monitoring, and temperature-controlled environments. These precautions are not limited to capital cities or urban centers. On the contrary: they are critical even for rural areas and for highly demanding clinical trials.

In this scenario, the adoption of best practices such as GMP (Good Manufacturing Practices) e GDP (Good Distribution Practices), in addition to AEO accreditation and compliance with RDCs, are essential to ensuring security, traceability, and regulatory compliance.

About FIC Company

We provide services in pharmaceutical logistics and international medical logistics, specializing in import, export, and transport of sensitive medications. With a focus on validated storage, digital traceability, batch centralization, and regulatory compliance, the company meets the standards required by Anvisa and global markets.

Learn more about our technical services by visiting our page on medical and pharmaceutical transportation logistics:

We uncomplicate your company's clinical and pharmaceutical logistics
Share on:
Se inscrever
Notificar de
guest
0 Comments
Mais Votado
Mais Recente Mais Antigo
Feedbacks Inline
Ver todos os comentários
Latest Posts: